A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
Crossref DOI link: https://doi.org/10.1186/s12931-017-0647-1
Published Online: 2017-11-02
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pudi, Krishna K.
Barnes, Chris N.
Moran, Edmund J.
Haumann, Brett
Kerwin, Edward
Funding for this research was provided by:
Theravance Biopharma
Mylan Inc.